Becton, Dickinson and Company BDX
Healthcare · Medical Instruments & Supplies · United States · S&P 500
Based on the available data, Becton, Dickinson and Company gets an algorithmic score of 54/100. It trades at 181.97 $, with a bullish technical trend (RSI 51.5) and 25.9% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Attractive free-cash-flow yield (5.4%).
- Low beta (0.45): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 31.43 |
| Forward P/E | 13.69 |
| PEG | 1.11 |
| P/B | 2.03 |
| EV/EBITDA | 10.73 |
| P/S | 2.20 |
| ROE % | 6.61 |
| ROA % | 4.34 |
| Gross margin % | 46.94 |
| Operating margin % | 15.73 |
| Net margin % | 4.19 |
| Revenue growth % (y/y) | 5.40 |
| Earnings growth % (y/y) | -31.40 |
| Revenue CAGR % | 4.99 |
| Earnings CAGR % | -1.93 |
| Debt/Equity % | 68.84 |
| Current ratio | 0.86 |
| FCF yield % | 5.39 |
| Dividend yield % | 2.31 |
| Payout % | 72.49 |
Returns
| 1 month | -3.4 % |
| 3 months | +21.0 % |
| 6 months | +19.2 % |
| YTD | +21.1 % |
| 1 year | +28.5 % |
| 3 years | -7.2 % |
| 5 years | +0.2 % |
Risk
| 1-year volatility | 25.9 % |
| Beta | 0.45 |
| 5-year max drawdown | -40.1 % |
| Sharpe 1A | 0.94 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.